Gary L. Rosner, ScD, on Bayesian Non-Inferiority

First International Summit on Interventional Pharmacoeconomics

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Issues in Oncology

The ASCO Post Staff

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Related Videos

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

New Research Offers Reassurance About Localized Prostate Cancer Prognosis

Avelumab Plus Cetuximab in Advanced Cutaneous Squamous Cell Carcinoma

Surgery vs Ablation in Small Hepatocellular Carcinoma

Chemoimmunotherapy for Advanced BTC 3-Year Overall Survival Update From the TOPAZ Trial

Optimizing the CAR to the Disease in B-Cell Malignancies